Category Archives: Cell Therapy

CAR-T and TCR-T therapies that involve engineering a patients own immune cells with antigen-specific receptors have revolutionized blood cancer treatment. Nowscientists at Duke-NUS Medical School are exploring the possibility of turning the approach against COVID-19.

The idea of using CAR/TCR-T cell therapy has already been proposed for treating chronic viral infections such as HIV and hepatitis B. Based on previous research, Antonio Bertoletti from Duke-NUS emerging infectious diseases research program suggest these immunotherapies might also be useful in treating SARS-CoV-2, the virus causing the current pandemic.

We demonstrated that T cells can be redirected to target the coronavirus responsible for SARS. Our team has now begun exploring the potential of CAR/TCR T cell immunotherapy for controlling the COVID-19-causing virus, SARS-CoV-2, and protecting patients from its symptomatic effects, Bertoletti said in a statement.

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

These types of therapies involve modifying patients' own T cells with either a chimeric antigen receptor (CAR) or a T-cell receptor (TCR) that can recognize specific antigens associated with cancer,and then guiding the immune cells to eradicate the targets when infused back into the patients.

In a 2011 article published in the Journal of Virology, Bertoletti led a team that generated TCR-T cells that can go after SARS, another coronavirus that caused a deadly outbreak in China and other countries in late 2002 and early 2003.

The team showed that those TCR-redirected T cells displayed a functional profile similar to that of SARS-specific memory CD8 T cells from people who recovered from SARS-CoV infection. Based on the findings, the researchers suggested that TCR-T cells represent a promising prophylactic or therapeutic treatment for SARS.

RELATED:How 'duoCAR-T' cells could clear HIV and prevent resurgence of virus reservoirs

CAR-T cells have been explored in other viruses. A research team from the Albert Einstein College of Medicine and the University of Pittsburgh, for example,designed duoCAR-T cells that target three sites on the HIV envelope glycoprotein. In the lab, the cell therapy eliminated up to 99% of immune cells infected with different strains of HIV.

Despite thepromise of T-cell therapies, however, Bertoletti and colleague Anthony Tanoto Tan cautioned about potential safety concerns of using them to treat viral infections affecting vital organs. For one thing, CAR-T treatments havebeen linked to the dangerous side effect called cytokine release syndrome, in which overreactive immune cells launch an inflammatory response that can destroy organs, they said in a recent Journal of Experimental Medicine commentary. Similar cytokine storm effects have been reported in somesevere COVID-19 patients, leading to potentially life-threatening lung inflammations.

[T]he infusion ofT cells stably expressingpathogen-specific CAR/TCR poses therisk that these T cells might proliferate and wipe out all the infected cells that might be the majority of the infected organ, Bertoletti and Tanoto Tan wrote in their article.

To addressthat problem, Bertoletti and colleagues are using mRNA electroporation to engineer CAR/TCR T cells, which they say can limit their inflammatory capability and shorten the functional activity. That may offer a safer way to use engineered immune cells to treat viral diseases.

Several organizations are also working on cell therapies for COVID-19. AlloVir and Baylor College of Medicine have teamed up to develop an off-the-shelf therapy that entails exposing donor T cells to cytokines combined with viral fragments so the new cells can target the novel coronavirus. Celgene spinoff Celularity just started clinical trial of its cancer treatment CYNK-001 for COVID-19. The drugturns placental stem cells into one-size-fits-all natural killer cells.

See more here:
Scientists explore using CAR-T and other engineered immune cells to target COVID-19 - FierceBiotech

Despite centuries-long efforts to develop cures for cancer, various forms of the disease will kill about 630,000 people in the U.S. in 2020. But hopes are rising for cell therapies sometimes called living medicines that can boost and adapt the natural cancer-fighting potential of the immune system in ways that conventional cancer treatments cannot match.

UC San Francisco researchers now have reported a new method to design and test cell therapies, one they expect will speed the development of new life-saving treatments not only for cancer, but for other diseases, too.

Cell therapy for cancer is a type of immunotherapy. Immune-system cells known as T cells are isolated from a patients blood and genetically modified in the lab, inserting or removing genes so the cells will better recognize and destroy tumors. These modified T-cells are grown in culture until they number in the hundreds of millions, and are then infused back into the patient through an IV drip.

One form of cell therapy, known as CAR-T-cell therapy, is already approved for certain blood cancers, but so far cell therapies have not been effective against the solid tumors that affect the breast, colon, brain, lung, and other tissues.

In 2018, a UCSF team led by immunologist Alex Marson, MD, PhD, along with Theo Roth, an MD/PhD student in the UCSF Medical Scientist Training Program, developed a breakthroughtechnique in which they used pulses of electricity (a method called electroporation) to enable CRISPR gene-targeting technology to quickly and efficiently reprogram T-cells with new functions.

Now, in a study published April 16, 2020, in Cell, the team hasadvanced this technique to power a high-throughput platform to evaluate the specificity and potency of many different potential cell therapies simultaneously comparable to the approach already widely used in industry to quickly screen large batches of small molecules to assess whether they would make effective drugs.

The UCSF researchers evaluated a library of 36 different DNA sequences, a selection based on educated guesses about which bits of genetic material, when spliced into T cells, might alter cell function to better fight cancer. They inserted the different sequences into different T cells to compare their best guesses head to head in the lab.

Rather than pursuing one educated guess at a time, we wanted a systematic way to compare different potential therapeutic edits head to head, said Marson, who serves as scientific director of biomedicine at the UCSF-UC Berkeley Innovative Genomics Institute (IGI) and is a Chan Zuckerberg Biohub Investigator. The ability to iterate fast and test different candidates against each other is what the field needs to move forward and have a discovery engine for next-generation cell therapies.

Many solid tumors express proteins that shield them from T cell attacks, so the researchers evaluated not only the modified cells ability to find cancer cells, but also their ability to accumulate robustly within tumors. Using a distinctive DNA barcode to track the modified T cells, the researchers raced them against one another in lab dishes and in vivo cancer models. This allowed them to identify specific gene modifications that give T cells the best ability to kill off solid-tumor cells in a lab dish and also more effectively fight a type of human skin cancer grown in mice.

Their new methods also enable researchers to measure specific patterns of gene activation within individual T cells to gain insight into how cellular functions have changed in the modified cells that fare best against tumors.

We now are working to further scale up and optimize this screening platform, said Roth, who with Marson is a co-founder of Arsenal Biosciences, a company funded in part by the Parker Institute for Cancer Immunotherapy that is focused on producing and testing new cell therapies. We believe this cell therapy development platform will make it possible for academics and industry to begin generating all sorts of genetically programed T cells targeted to specific cancers as well as other medical applications.

Follow this link:
CRISPR-Based 'Discovery Engine' for New Cell Therapies to Advance Cancer Treatments - UCSF News Services

The rapid growth of biopharma is causing a shift to a new paradigm for the drug development and delivery model. In the same manner that the personal computing industry grew and developed business models that fit the way products were sourced, constructed and delivered, a business model for biopharma is taking shape.

Jeff Galvin, CEO of American Gene Technologies (AGT), had 30 years of business and entrepreneurial experience in Silicon Valley during the formative years of the personal computing and internet era. He left retirement as an Angel Investor in real estate and high tech in 2008 to found AGT and lead it in developing a bank for Lentiviral vectors with different characteristics for use with its gene delivery platform.

The use of these vectors with this platform will save time and money in drug development, Galvin said as he shared his vision for the biopharma industry with BioSpace.

The Personal Computing Industry as a Model

In the early days of the personal computing industry, a computer company was responsible for its product from start to finish. This could not only include hardware and software but peripherals as well. As the industry grew and matured, Galvin explained, other industries grew up around the personal computer industry. These were not mere opportunities to outsource; these were companies acting with their own plans and interests in mind. The result of this was the development of software by vendors having no more to do with a computer manufacturer than the ability to code in a language that the computer would recognize.

This autonomy made it possible for companies to specialize in certain types of software, even to the point of supporting one specific app. The need to save data and put new software onto a computer led to an industry based on physical storage media. As computer technology grew, the precise product - floppy to CD and onward - evolved. Over time, it has led to cloud-based computing in which the software no longer comes on a physical medium, says Galvin. This uncoupling of software and peripherals from the computer hardware itself has given rise to exponential growth in applications and the ability to use computers to solve myriad problems.

American Gene Technology (AGT) Offers a Delivery System

Similarly, as the gene and cell therapy industries grow, companies that specialize in one aspect of the drug development process or in one application will be able to focus on that one part. As long as what is developed will work with the human body, genes and cell therapy can be used to alter the DNA. For AGT, this means collaborating with researchers who are looking for a delivery system for the innovative treatments they develop.

Galvin explains, AGTs platform is a broad set of reusable components and fundamental innovations on the use of any or all viral vectors to reliably deliver genetic changes to cells that are safe, predictable, and that maintain therapeutic expression for the duration necessary for the mission of mitigating the disease state. The viral vectors are the diskettes that carry the software updates to your DNA, the operating system, of your organic computer, aka the human cell. Rather than machines and code, AGT delivery platform makes it possible to use the human body and its genes to treat disease.

AGT began with lentiviruses because, Galvin explains, it happens to be what we believed was the right vector delivery on our three lead programs of HIV, phenylketonuria (PKU), and cancer. This was because the lentivirus matched the attributes we were looking for in terms of cargo space for genetic constructs.

With the ability to deliver the genes needed to modify specific cells types or tissue, AGT is able to provide this capability for a range of therapies. Currently, AGT is working to cure HIV through the use of its lentivirus delivery platform. With a viral vector as the diskette used to load the genetic construct into that vector as the software, the virus will do the work of delivering the critical change to a cell.

The Future

AGT views itself as a vector agnostic delivery company, Galvin explained. In the future, they will work with whichever delivery vector is needed. As delivery vectors improve, AGT will have the capability of combining more of their components on a single vector, resulting in the opportunity to address increasingly complex diseases.

We will look to partners that pioneer new methods of modifying DNA in cells (even CRISPR when it becomes as reliable and safe as lentivirus), and we will continue to revise and optimize our drugs to utilize the capabilities that those partners develop, Galvin said.

To date, AGT has seen that each time we start a new drug, we find that our previous R&D yielded components and techniques that provide a base, the starting point, that is up to 80% of the next drug candidate, Galvin said.

This efficiency is AGTs strategy for remaining competitive in this disruptive industry. It is also necessary if the benefits of the gene and cell therapy revolution are to achieve the reductions in cost necessary to reach the greatest number of patients in need.

Galvin believes the evolution of the gene and cell therapy technology and industry will track closely with the evolution of the computer industry. His vision is an encouraging one for the rest of us. If the comparison holds, well see that as companies find their place in the industry and hone their offering, the advances to be made will be rapid and significant. The result will be improved treatments, along with treatments for diseases that are currently considered incurable.

-Please click here for more information on our contributing writer,Gina Hagler.

View original post here:
AGT CEO Jeff Galvin on the Future of the Gene and Cell Therapy Industry - BioSpace

CAMBRIDGE, Mass., April 23, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first quarter 2020 financial results and corporate update conference call and live audio webcast onThursday, April 30that 8:30 a.m. EDT. Interested participants may access the conference call by dialing (844) 826-0619 (domestic) or (315) 625-6883 (international) and referring to conference ID number 4855738. To join the live webcast, please visit the presentation page of the investor relations section of the Genocea website athttps://ir.genocea.com/events-and-presentations. A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.

Additionally, Genocea will host a virtual KOL symposium with a live Q&A providing a brief review of the current T cell therapy landscape including the evolution of TIL and TCR therapy utility, and the need for new approaches to better patient outcomes on Tuesday, May 12th at 12 p.m. EDT. Members of the Genocea management team will also provide an overview of the development of GEN-011, a potential best-in-class solid tumor adoptive T cell therapy. More details will follow on accessing the virtual KOL symposium.

About Genocea Biosciences, Inc.Genoceas mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS platform comprehensively profiles each patients T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and expect preliminary clinical results in Q2/Q3 2020, and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood, for which we intend to file an Investigational New Drug Application in the second quarter of 2020. To learn more, please visit http://www.genocea.com.

Forward-Looking StatementsThis press release includes forward-looking statements, including statements relating to GEN-009 and GEN-011, within the meaning of the Private Securities Litigation Reform Act. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Genocea cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties that change over time. Applicable risks and uncertainties include those identified under the heading "Risk Factors" included in Genocea's Annual Report on Form 10-K for the year ended December 31, 2019 and any subsequent SEC filings. These forward-looking statements speak only as of the date of this press release and Genocea assumes no duty to update forward-looking statements, except as may be required by law.

Investor Contact:Dan Ferry617-430-7576daniel@lifesciadvisors.com

See the article here:
Genocea to Host First Quarter 2020 Corporate Update Conference Call & WebcastVirtual KOL symposium scheduled for May 12th to review GEN-011 ...

Mrinsights.bizhas published a new report titled GlobalAnimal Stem Cell TherapyMarketGrowth 2020-2025 which comprises new statistical data on the changing market scenario and initial and future assessment of the market. The report covers a wide range of business aspects global Animal Stem Cell Therapy trends, future forecasts, growth opportunities, key end-user industries, and market players. The report analyzes the recent developments, investment opportunities, and probable threats in the market. It closely looks at the markets all-purpose evaluation and depicts the important data associated with the global market.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/232664/request-sample

The report assesses the demand-side and supply-side trends in the global Animal Stem Cell Therapy market. Various segments are scrutinized that involve end-users, regions, and players on the basis of demand patterns, and prospect for 2020 to 2025 time-period. The research report contains a comprehensive database on future market estimation based on historical data analysis. Key players are listed with major collaborations, mergers & acquisitions and upcoming and trending innovation. Primary research involves interviews, news sources and information booths. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

Understanding The Competitive Scenario:

Competitive landscape analysis is presented which involves the global Animal Stem Cell Therapy market share of major players, along with the new projects and strategies adopted by players in the past five years. Comprehensive company profiles comprise the product offerings, key financial information, recent developments, SWOT analysis, capacity, production, price, revenue, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, and strategies employed by the major market players. Additionally, the report covers insights into the production and capacities in terms of manufacturing with price fluctuations of raw materials, process in-flow rate product cost, and production value.

Considering market analysis, the profiled list of companies in the report is:Medivet Biologics LLC, Animal Cell Therapies, VETSTEM BIOPHARMA, U.S. Stem Cell, Inc, VetCell Therapeutics, J-ARM, Kintaro Cells Power, Celavet Inc., Animal Stem Care, Magellan Stem Cells, Cell Therapy Sciences, Animacel

Currently, the research report gives special attention and focus on the following regions:Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia, Spain), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries).

Moreover, the report identifies potential customers and suppliers as well as gives an analysis of the companys business structure, operations, major products and services, and business strategy. The study helps you understand the companys core strengths, weaknesses, opportunities, and threats. The report shows factual data about the global Animal Stem Cell Therapy market in the worldwide area, for example, production chain, manufacturing capacity, sales volume, and revenue.

ACCESS FULL REPORT:https://www.mrinsights.biz/report/global-animal-stem-cell-therapy-market-growth-2020-2025-232664.html

The Scope of The Global Animal Stem Cell Therapy Report:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

See more here:
Global Animal Stem Cell Therapy Market 2020 Future Scenario, Industry Growth Insights and Production Analysis 2025 - Bandera County Courier

The Animal Stem Cell Therapy report provides independent information about the Animal Stem Cell Therapy industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Animal Stem Cell Therapy MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Animal Stem Cell Therapy Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Animal Stem Cell Therapy Market: Products in the Animal Stem Cell Therapy classification furnish clients with assets to get ready for tests, tests, and evaluations.

Animal Stem Cell Therapy Market Report Covers the Following Segments:

Segment1: By Type, Dogs, Horses, Others, By Application, Veterinary Hospitals, Research Organizations

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Animal Stem Cell Therapy Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Animal Stem Cell Therapy Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Animal Stem Cell Therapy Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Animal Stem Cell Therapy Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Animal Stem Cell Therapy Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Animal Stem Cell Therapy Market.

Market Forecast:Here, the report offers a complete forecast of the global Animal Stem Cell Therapy Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/at-1905-cagr-pop-up-cinema-market-size-to-surpass-us-197229-million-by-2025-2020-04-24

https://www.marketwatch.com/press-release/at-1905-cagr-pop-up-cinema-market-size-to-surpass-us-197229-million-by-2025-2020-04-24

https://www.marketwatch.com/press-release/ipaas-integration-platform-as-a-service-market-size-share-application-analysis-regional-outlook-growth-trends-top-key-players-and-competitive-strategiesforecast-to-2025-2020-04-24?tesla=y

https://www.marketwatch.com/press-release/microwave-transmission-equipment-market-2020-share-trends-segmentation-and-forecast-by-2025-cagr-of-314-2020-04-24-61763810?tesla=y

http://marketwatch.com/press-release/military-drone-market-share-size-future-demand-global-research-top-leading-player-emerging-trends-region-by-forecast-to-2025-2020-04-24?tesla=y

Read the rest here:
Animal Stem Cell Therapy Market Is Set To Experience Revolutionary Growth By 2025 - Cole of Duty

Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo), a genomic medicine company, have announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrifys proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamos zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.

Mogrify is delighted to announce its second commercial deal with a US biopharma and the first in the exciting field of T cell immunotherapy, said Dr. Darrin M. Disley OBE, CEO, Mogrify. The combination of Mogrifys proprietary systematic cell conversion technology and Sangamos regulatory T cell platform and proprietary ZFP platform is a natural fit. Sangamo is at the forefront of the development of a world-class engineered ZFP genome editing platform and we are very happy to be partnering with such an innovative company.

This license agreement provides Sangamo with access to Mogrifys cell conversion technology, which will diversify our options as we develop off-the-shelf allogeneic CAR-Treg cell therapies, said Jason Fontenot, SVP, Head of Cell Therapy at Sangamo. We expect this collaboration to accelerate our development of scalable and accessible CAR-Treg cell therapies, so that we can potentially deliver treatments to patients with inflammatory and autoimmune diseases more rapidly.

Mogrifys technology enables the transformation of any human cell type into any other human cell type. This transformation is achieved using transcription factors or small molecules identified using proprietary big data technologies. iPSCs and ESCs provide an evergreen starting material for the generation of Tregs, and facilitate more complex engineering and greater manufacturing scalability, potentially enabling the resulting therapies to be more cost-effective and thus more accessible to larger patient populations.

Under the terms of the agreement, Mogrify will be responsible for the discovery and optimization of the cell conversion technology from iPSCs or ESCs to regulatory T cells, and Sangamo will be granted exclusive rights to use Mogrifys technology to create Tregs from iPSCs or ESCs. Sangamo expects to then use its ZFP gene-engineering technology and therapeutic development capabilities to transform these Tregs into novel off-the-shelf allogeneic CAR-Treg cell therapy candidates and hopes to take them through clinical development through to registration for the treatment of inflammatory and autoimmune diseases.

Want more of the latest science news straight to your inbox? Become a SelectScience member for free today>>

Go here to see the original:
Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify's iPSC- and ESC-derived regulatory T cells - SelectScience

Pluristem Therapeutics or PLX cell therapyuses placentas to grow smart cells, and programs them to secrete therapeutic proteins in the bodies of sick people. It has just treated its first American COVID-19 patient after treating seven Israelis. The patients were suffering from acute respiratory failure and inflammatory complications associated with Covid-19. Now, this theraphy is being touted as a possible 'cure'' for the deadly coronavirus with scientisst conducting varied researches on the same. In an exclusive interaction with India TV, doctors from India and abroadcame together for discussing about how effective can cell therapy be in treating coronavirus. Dr Solomon from Israel, Dr Anil Kaul from the US, DrSanjeev Chaubey from Shanghai and Dr Padma Srivastv and Dr Harsh Mahajan from India threw light upon the stem cell therapy and the possibility of incorporating the same in treating COVID-19 pateints.

Latest News on Coronavirus

Fight against Coronavirus: Full coverage

Follow this link:
How effective is PLX cell therapy in treating coronavirus? Experts answer all queries and more - India TV News

(MENAFN - GetNews) The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) market report provides current treatment practices, emerging therapies, CAR T-Cell Therapy for Non-Hodgkin's lymphoma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Non-Hodgkin's lymphoma market size from 2017 to 2030 segmented by US and EU markets.

DelveInsight's CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) - Market Insights and Market Forecast-2030 ' report delivers an in-depth understanding of the CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) and market trends in the 6MM, i.e., the United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).

CAR-T cell therapy market for NHL

The CAR T-Cell Therapy for Non-Hodgkin's lymphoma (NHL) market report provides current treatment practices, emerging therapies, CAR T-Cell Therapy for Non-Hodgkin's lymphoma market share of the individual therapies, current and forecasted CAR T-Cell Therapy for Non-Hodgkin's lymphoma market size from 2017 to 2030 segmented by US and EU markets. The Report also covers current CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Marketed Therapies in CAR-T cell therapy market for NHL

Chemotherapies, radiation therapies and immunotherapies are either used in combination or alone, depending upon the severity, success rate, age and several other factors. However, CAR-T cell therapy promises one-time treatment and cancer-free life. The available therapeutics treatment options in CAR T-Cell Therapy market for Non-Hodgkin lymphoma aim to kill the leukemia cells in the blood and bone marrow.

The approval of Yescarta was proved to be the light of the day for the group of cancer patients who were left with a few other options, and those with certain types of lymphoma that had not responded to previous treatments.

Emerging Therapies in CAR-T cell therapy market for NHL

This section focusses on the rate of uptake of the potential CAR T-Cell Therapies recently launched in the Non-Hodgkin's lymphoma market or expected to get launched in the market during the study period 20172030. The analysis covers Non-Hodgkin's lymphoma market uptake by CAR T-Cell Therapies; patient uptake by therapies; and sales of each therapy.

The approval of the novel CAR-T cell therapy attracted many pharma investors and pharma companies, highlighting the bright scope of CAR-T cell therapies in oncology.

Several companies, including Celgene , and Gilead , are working to fuel the CAR-T cell therapy market for Non-Hodgkin lymphoma. The expected launch of Lisocabtagene maraleucel (also known as JCAR017) of Celgene 's, (a BMS company) and KTE-X19 by Gilead will significantly drive the NHL market in the near future.

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Non-Hodgkin's lymphoma (NHL) emerging CAR T-Cell Therapies.

Request for Sample Pages

CAR-T cell therapy market for NHL: Forecast

As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030.

Among the EU-5 countries, Germany, Italy and France are observed to be among top holders of the largest CAR T-Cell Therapy market share for Non-Hodgkin lymphoma followed by UK and Spain.

Know more about the scenario of CAR-T Market for NHL

Scope of the Report

Table of Contents

1 Key Insights

2 Executive Summary

3 CAR T-Cell Therapy for NHL Market Overview at a Glance

4 CAR T-Cell Therapy: Background and Overview

5 Treatment Algorithm, Current Treatment, and Medical Practices

6 Unmet Needs

7 Key Endpoints of NHL Treatment

8 Marketed CAR T-Cell Therapies for NHL

8.2 KYMRIAH: NOVARTIS

8.3 YESCARTA: Kite Pharma (Gilead Sciences)

9 Emerging CAR T-Cell Therapies for NHL

9.1.1 KTE-X19: Gilead Sciences

9.1.2 JCAR017: Celgene Corporation (a BMS company)

10 CAR T-Cell Therapy for NHL: Six Major Market Analysis

11 Attribute analysis

12 6MM: Market Outlook

13 CAR T-Cell Therapy for NHL Clinical Trials in 6MM

14 KOL Views CAR T-Cell Therapy for NHL

15 Market Drivers

16 Market Barriers

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.

Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Vinita Rakheja Email: Send Email Phone: 9193216187 Address: 304 S. Jones Blvd #2432 Country: United States Website: http://www.delveinsight.com/

MENAFN2204202000703268ID1100068707

See the original post here:
CAR-T cell therapy Market for Non-Hodgkin Lymphoma is expected to touch USD 2796.2 Million by 2030 - MENAFN.COM

Heres recently issued report on the Global CAR T-Cell Therapy for Multiple Myeloma Market that allows you to offer a brief analysis of the market size, demand, supply chain, distribution channels, futuristic trends, market growth elements and so on. It offers a comprehensive analysis of assorted business aspects like global CAR T-Cell Therapy for Multiple Myeloma market trends, recent technological advancements, market shares, size and new innovations. What is more, this analytical knowledge has been compiled through knowledge searching techniques like primary and secondary analysis for CAR T-Cell Therapy for Multiple Myeloma industry. Moreover, an professional team of researchers throws lightweight on numerous static additionally as dynamic aspects of the worldwide CAR T-Cell Therapy for Multiple Myeloma market.

Obtain sample copy of CAR T-Cell Therapy for Multiple Myeloma market report: https://calibreresearch.com/report/global-car-tcell-therapy-multiple-myeloma-market-3740#request-sample

Geographically, the worldwide CAR T-Cell Therapy for Multiple Myeloma market has been analyzed in numerous regions like North America, geographical region, geographical region, Asia-Pacific, Africa, Europe and Asian nation. The worldwide CAR T-Cell Therapy for Multiple Myeloma market region is dominating this market among the forthcoming future. Worldwide CAR T-Cell Therapy for Multiple Myeloma market is that the skilled and correct study of assorted business views like key players, key geographies, divers, restraints, opportunities and challenges. This global analysis report has been mass on the concept of assorted market segments and sub-segments associated with the worldwide market.

Global CAR T-Cell Therapy for Multiple Myeloma market competition by prime manufacturers, with CAR T-Cell Therapy for Multiple Myeloma sales volume, value (USD/Unit), revenue (Million USD) and market share for each manufacturer. The report provides an in-depth analysis of the worldwide CAR T-Cell Therapy for Multiple Myeloma Market progressing to cut back time to plug for products and services, cut back operational value, improve accuracy and operational performance. Besides this, the report elaborates crucial aspects such as fresh product establishment, greater expenditure in R&D and increasing demand in the manufacturing differentiable growth opportunities in the CAR T-Cell Therapy for Multiple Myeloma Market globally.

Checkout Inquiry For Buying or Customization of CAR T-Cell Therapy for Multiple Myeloma Market Report: https://calibreresearch.com/report/global-car-tcell-therapy-multiple-myeloma-market-3740#inquiry-for-buying

The complete profile of the manufacturers are mentioned. And so the capability, production, price, revenue, cost, gross, margin of profit, sales volume, sales revenue, consumption, rate of growth, import and export, future strategies and therefore the technological developments that they are creating are also enclosed among the report. The historical knowledge and forecast knowledge from 2020 to 2026.

Leading companies reviewed in the CAR T-Cell Therapy for Multiple Myeloma report are:

Juno TherapeuticsKite PharmaNovartisCollectis

The CAR T-Cell Therapy for Multiple Myeloma Market report is segmented into following categories:

The product segment of the report offers product market information such as demand, supply and market value of the product.

The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.The CAR T-Cell Therapy for Multiple Myeloma market report is segmented into Type by following categories;MonotherapyCombination Therapy

The CAR T-Cell Therapy for Multiple Myeloma market report is segmented into Application by following categories;Multiple MyelomaRefractory or Relapsed Multiple Myeloma

Checkout FREE Report Sample of CAR T-Cell Therapy for Multiple Myeloma Market Report for Better Understanding: https://calibreresearch.com/report/global-car-tcell-therapy-multiple-myeloma-market-3740#request-sample

The report provides substantial knowledge relating to the market share that every one in every of these firms presently garner across this business, in tandem with the market share that they are expected to amass by the highest of the forecast period. Also, the report elaborates on details regarding the products manufactured by every of these companies, that may facilitate new entrants and outstanding stakeholders work on their competition and strategy portfolios. To not mention, their decision-making method is vulnerable to get easier on account of the actual fact that the CAR T-Cell Therapy for Multiple Myeloma System market report additionally enumerates a gist of the products value trends and so the profit margins of each firm among the industry.

This will enable the readers to focus on CAR T-Cell Therapy for Multiple Myeloma market product specifications, current competitive manufacturers in CAR T-Cell Therapy for Multiple Myeloma market and also the market revenue with gain. Worldwide Industry Analyze CAR T-Cell Therapy for Multiple Myeloma Market by competitive manufacturers, regions and applications of CAR T-Cell Therapy for Multiple Myeloma market, forecast up to 2026. This report analyses the scope of CAR T-Cell Therapy for Multiple Myeloma market. This will be achieved by CAR T-Cell Therapy for Multiple Myeloma previous historical information, analysing qualitative insights info, demonstrable projections regarding global CAR T-Cell Therapy for Multiple Myeloma market size.

Read the original here:
Global CAR T-Cell Therapy for Multiple Myeloma Market (impact of COVID-19) 2020-2026 Juno Therapeutics, Kite Pharma, Novartis, Collectis - NJ MMA News